TFFP - TFF Pharmaceuticals gets Health Canada approval for niclosamide COVID-19 human trials

TFF Pharmaceuticals (TFFP +0.3%) has received approval from Health Canada to begin a Phase 1 trial of a dry powder formulation of niclosamide, an antiviral treatment with potential to address COVID-19 and other infectious diseases. The company anticipates the first patient will be dosed in the study in November and that enrollment will be completed by early Q1 2022. Preclinical studies of inhaled dry powder formulation of niclosamide showed a seven-fold reduction in lung viral load in hamsters when administered 24 hours after inoculation with SARS-CoV-2, the company said.

For further details see:

TFF Pharmaceuticals gets Health Canada approval for niclosamide COVID-19 human trials